Micafungin - The newest echinocandin

Zelalem Temesgen, Jason Barreto, Sandro Vento

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it also has utility for the treatment of infections caused by Aspergillus species. However, its approved indications remain for the treatment of both invasive and esophageal candidiasis and for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is generally well tolerated with few significant adverse effects.

Original languageEnglish (US)
Pages (from-to)469-478
Number of pages10
JournalDrugs of Today
Volume45
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Echinocandins
Candida
Infection
Invasive Candidiasis
Azoles
Hematopoietic Stem Cell Transplantation
Aspergillus
micafungin
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Micafungin - The newest echinocandin. / Temesgen, Zelalem; Barreto, Jason; Vento, Sandro.

In: Drugs of Today, Vol. 45, No. 6, 06.2009, p. 469-478.

Research output: Contribution to journalArticle

Temesgen, Zelalem ; Barreto, Jason ; Vento, Sandro. / Micafungin - The newest echinocandin. In: Drugs of Today. 2009 ; Vol. 45, No. 6. pp. 469-478.
@article{a7da0802b8a5462eba1f09b7cac4d8d2,
title = "Micafungin - The newest echinocandin",
abstract = "Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it also has utility for the treatment of infections caused by Aspergillus species. However, its approved indications remain for the treatment of both invasive and esophageal candidiasis and for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is generally well tolerated with few significant adverse effects.",
author = "Zelalem Temesgen and Jason Barreto and Sandro Vento",
year = "2009",
month = "6",
doi = "10.1358/dot.2009.45.6.1378277",
language = "English (US)",
volume = "45",
pages = "469--478",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "6",

}

TY - JOUR

T1 - Micafungin - The newest echinocandin

AU - Temesgen, Zelalem

AU - Barreto, Jason

AU - Vento, Sandro

PY - 2009/6

Y1 - 2009/6

N2 - Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it also has utility for the treatment of infections caused by Aspergillus species. However, its approved indications remain for the treatment of both invasive and esophageal candidiasis and for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is generally well tolerated with few significant adverse effects.

AB - Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it also has utility for the treatment of infections caused by Aspergillus species. However, its approved indications remain for the treatment of both invasive and esophageal candidiasis and for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is generally well tolerated with few significant adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=70350074594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350074594&partnerID=8YFLogxK

U2 - 10.1358/dot.2009.45.6.1378277

DO - 10.1358/dot.2009.45.6.1378277

M3 - Article

VL - 45

SP - 469

EP - 478

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 6

ER -